Jacob graduated from the University of Maryland with degrees in journalism and biology. He's previously reported on M&A at TheDeal, politics at McClatchy DC and education research at Education Week. His main interests include RuPaul's Drag Race, anything from the McDonalds menu and strong shoe game. He has loud opinions about avocado toast and Vine ending.
880 articles by Jacob Bell
-
ICER sees current DMD therapies as too pricey, but notes data limitations
May 23, 2019 -
Lilly drug scores in Phase 2 Crohn's study
May 22, 2019 -
Merck puts $1B more into oncology, with kidney cancer a focus
May 21, 2019 -
UK charity sells Keytruda rights for $1.3B
May 20, 2019 -
The NASH dash runs into some early hurdles
May 17, 2019 -
No one knows the size of the NASH market
May 16, 2019 -
On the path to patients, NASH drugs may hit a payer roadblock
May 15, 2019 -
Will a big needle burst the NASH bubble?
May 14, 2019 -
Bayer pumping $150M more into biologics
May 13, 2019 -
Takeda offloads dry eye drug to Novartis for $3.4B
May 9, 2019 -
Gilead goes after a young biotech's data to break into kidney diseases
May 8, 2019 -
Catalyst dives as FDA approves rival's rare disease drug
May 7, 2019 -
Lundbeck builds out brain drug pipeline with $250M acquisition
May 6, 2019 -
Gilead's first move under new chief is to untether Kite
May 3, 2019 -
Amid outbreaks, Merck ramps up measles vaccine manufacturing
May 2, 2019 -
Pain, cancer, immunology drugs aren't bringing the relief Lilly needs
April 30, 2019 -
Elanco trying to fetch more out of specialty veterinary drugs
April 29, 2019 -
Praluent's lower list price isn't yielding better sales yet
April 26, 2019 -
Another late-stage miss knocks Gilead from its leading NASH position
April 25, 2019 -
Biogen points to M&A power as Wall Street presses for less risky programs
April 24, 2019 -
Lilly selling antibiotic rights, manufacturing plant in China
April 23, 2019 -
Lilly bets bigger on RNA drugs, with latest deal targeting immunology
April 22, 2019 -
Sandoz takes United Therapeutics to court for 'anticompetitive' behavior
April 18, 2019 -
Gilead taps into machine learning to find new NASH drugs
April 16, 2019 -
Catalent to buy Paragon for $1.2B as gene therapy demand grows
April 15, 2019